ORIC Pharmaceuticals appoints Angie You to board, Carl Gordon resigns

Oric Pharmaceuticals, Inc.

Carl Gordon, Ph.D., CFA, resigned as director voluntarily, no disagreement with board.
Angie You, Ph.D., appointed as Class II director, term expires at 2022 annual meeting.
You is CEO of Amunix Pharmaceuticals; previously chief business officer at Sierra Oncology and Aragon.
She receives annual cash retainer of $35,000, committee fees, and stock option for 33,250 shares.
No reportable transactions under Item 404(a) between You and ORIC.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carl Gordon

director

ORIC · Oric Pharmaceuticals, Inc.

Effective: 2021-11-09
Filed: November 10, 2021, 6:59 PM ET

On November 9, 2021, Carl Gordon, Ph.D., C.F.A. submitted his resignation as a director of ORIC Pharmaceuticals, Inc.

Appointed

Angie You

director

ORIC · Oric Pharmaceuticals, Inc.

Effective: 2021-11-09
Filed: November 10, 2021, 6:59 PM ET

On November 9, 2021, the Board appointed Angie You, Ph.D. to serve as a Class II director, with a term expiring at the Company’s 2022 annual meeting of stockholders, as well as serve as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl Gordon resigned as director at Oric Pharmaceuticals, Inc..

Action: resigned
Role: director

Exact text from the filing

On November 9, 2021, Carl Gordon, Ph.D., C.F.A. submitted his resignation as a director of ORIC Pharmaceuticals, Inc.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Angie You was appointed as director at Oric Pharmaceuticals, Inc..

Action: appointed
Role: director

Exact text from the filing

On November 9, 2021, the Board appointed Angie You, Ph.D. to serve as a Class II director, with a term expiring at the Company’s 2022 annual meeting of stockholders, as well as serve as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee.

View on SEC.gov

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-326034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.